Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Predictive Oncology Inc

Company price
6.8601 USD 1.38 ( 25.18%)
Last update at 2026-01-14T14:30:00Z
VOLUME
39840
Market Cap
8.55M

Momentum Score

…

Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development. The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.86
Low
7.44
High
52 Week Price Range
1.12
Low
7.12
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.48
Dividend Yield
-
Revenue TTM
1.78M
Revenue Per Share
0.44
Gross Profit TTM
1.00M
Debt / Equity
0.35
ROE
-93.11%
Net Debt
-5.87M
ROCE
-145.88%
Diluted EPS TTM
-4.90

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -25.74M -20.32M -25.88M -19.39M -10.09M
Net income -36.21M -19.66M -37.70M -27.56M -10.09M
Selling general administrative 11.11M 10.93M 10.35M 9.78M 4.63M
Selling and marketing expenses 1.36M 0.77M 0.58M 1.91M 2.37M
Gross profit 1.00M 0.93M 0.81M 0.88M 1.00M
Reconciled depreciation 1.31M 1.34M 1.02M 0.70M 0.15M
Ebit -15.27M -13.47M -0.67M -13.77M -7.86M
Ebitda -3.30M -6.68M 0.36M -4.90M -7.71M
Depreciation and amortization 11.96M 6.79M 1.02M 8.87M 0.15M
Non operating income net other - - -1.81M - -
Operating income -15.27M -13.47M -0.67M -13.77M -7.86M
Other operating expenses 16.77M 14.89M 13.74M 15.19M 9.27M
Interest expense 10.65M 12.30M 0.00M 0.00M 0.00M
Tax provision 0.00M -0.66M - - -
Interest income - - - 5.72M 2.29M
Non recurring - - 12.88M - -
Income tax expense 10.47M -0.66M 11.82M 8.17M -2.23M
Total revenue 1.51M 1.42M 1.25M 1.41M 1.41M
Total operating expenses 16.27M 14.41M 13.29M 14.65M 8.86M
Cost of revenue 0.51M 0.49M 0.45M 0.53M 0.42M
Total other income expense net -10.47M -6.85M -25.22M -5.62M -2.23M
Net income from continuing ops -25.74M -19.66M -25.88M -19.39M -10.09M
Net income applicable to common shares -25.74M -19.66M -26.44M -19.68M -10.09M
Preferred stock and other adjustments - - 0.55M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 14.42M 25.73M 43.77M 13.06M 22.38M
Intangible assets 0.25M 0.25M 3.96M 3.40M 3.65M
Other current assets 0.52M 0.53M 0.51M 0.29M 0.16M
Total liab 6.15M 3.97M 3.51M 10.42M 11.14M
Total stockholder equity 8.27M 21.77M 40.27M 2.64M 11.23M
Other current liab 1.63M 2.24M 1.39M 2.88M 2.42M
Common stock 0.04M 0.79M 0.66M 0.20M 0.04M
Capital stock 0.04M 0.79M 0.66M 0.20M 0.08M
Retained earnings -167.76M -153.78M -128.04M -108.38M -82.50M
Other liab - - 0.03M 0.24M -
Good will - 0.00M 6.86M 2.81M 15.69M
Other assets - 0.08M 0.17M 1.51M -
Cash 8.73M 22.07M 28.20M 0.68M 0.15M
Total current liabilities 3.95M 3.88M 3.24M 9.34M 10.87M
Current deferred revenue 0.31M 0.60M 0.19M 0.05M 0.04M
Net debt -5.87M -21.89M -27.32M 5.20M 5.37M
Short term debt 0.67M 0.09M 0.64M 5.03M 5.26M
Short long term debt 0.15M - - 4.43M 4.80M
Short long term debt total 2.86M 0.18M 0.88M 5.87M 5.53M
Other stockholder equity 175.99M 174.76M 167.65M 110.83M 93.65M
Property plant equipment - 2.05M 3.33M 5.22M 2.24M
Total current assets 10.08M 23.36M 29.46M 1.51M 0.80M
Net tangible assets - 21.51M 29.44M -3.57M -8.14M
Net receivables 0.33M 0.33M 0.35M 0.26M 0.30M
Inventory 0.49M 0.43M 0.39M 0.29M 0.19M
Accounts payable 1.34M 0.94M 1.02M 1.37M 3.16M
Accumulated other comprehensive income -0.00M - - - -0.77M
Common stock total equity - - - 0.20M 0.04M
Preferred stock total equity - - - 0.00M -
Retained earnings total equity - - - -108.38M -
Non currrent assets other 0.13M 0.08M 0.17M 0.12M 21.58M
Non current assets total 4.34M 2.37M 14.31M 11.55M 21.58M
Capital lease obligations 2.71M 0.18M 0.88M 1.44M 0.73M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.48M -10.61M -0.17M -0.60M -1.11M
Change to liabilities -0.04M -0.30M -1.64M 0.38M 0.32M
Total cashflows from investing activities -0.48M -10.61M -0.17M -0.60M -1.11M
Net borrowings - -4.16M 1.29M 1.54M 2.19M
Total cash from financing activities 6.72M 50.34M 12.95M 9.32M 5.79M
Change to operating activities 0.92M -0.78M 0.46M 1.26M 0.63M
Net income -25.74M -19.66M -25.88M -19.39M -10.09M
Change in cash -6.13M 27.52M 0.53M -0.01M -0.60M
Begin period cash flow 28.20M 0.68M 0.15M 0.16M 0.77M
End period cash flow 22.07M 28.20M 0.68M 0.15M 0.16M
Total cash from operating activities -12.37M -12.21M -12.26M -8.73M -5.29M
Issuance of capital stock 6.74M 51.20M 9.95M 7.98M 2.96M
Depreciation 1.31M 1.34M 1.02M 0.70M 0.15M
Other cashflows from investing activities - - 0.13M -0.82M -1.12M
Dividends paid - 4.51M 2962.77M - -
Change to inventory -0.04M -0.10M -0.09M 0.09M 0.02M
Change to account receivables 0.02M -0.02M 0.07M 0.14M -0.10M
Sale purchase of stock -0.03M -0.01M 2962.77M 7.99M 3.61M
Other cashflows from financing activities -0.48M 7.83M 4.48M 4.83M 2.84M
Change to netincome 11.19M 7.06M 12.57M 6.06M 3.38M
Capital expenditures 0.48M 0.96M 0.36M 0.03M 0.23M
Change receivables - - 0.07M - -
Cash flows other operating - - 0.92M - -
Cash and cash equivalents changes - - 0.53M - -
Change in working capital 0.87M -1.19M -1.21M 1.87M 0.88M
Stock based compensation - 6.80M - - -
Other non cash items 11.19M 1.17M 13.81M 8.08M 3.77M
Free cash flow -12.85M -13.17M -12.62M -8.76M -5.52M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
POAI
Predictive Oncology Inc
1.38
25.18%
6.86 - - 4.02 0.86 0.72 -0.10
ISRG
Intuitive Surgical Inc
3.70
0.84%
443.59 43.30 31.35 12.25 7.35 11.63 30.22
ESLOF
EssilorLuxottica Société anonyme
-8.90
4.32%
197.19 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA
1.64
1.66%
100.55 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company
2.32
1.08%
218.03 31.62 13.76 2.25 2.04 2.93 13.40

Profile*

Predictive Oncology Inc

Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development. The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.

2915 Commers Drive, Eagan, MN, United States, 55121

651 389 4800

34

Name Title Year Born
Mr. Raymond F. Vennare CEO & Chairman 1952
Mr. Robert L. Myers M.B.A. CFO & Sec. 1955
Mr. Richard L. Gabriel B.S., B.Sc, M.B.A., MBA Sr. VP of R&D 1949
Dr. Julia Kirshner Ph.D. Chief Scientific Officer NA
Ms. Theresa Ferguson Sr. Director of Marketing NA
Ms. Pamela Bush M.B.A., Ph.D. Sr. VP of Strategic Sales & Bus. Devel. NA
Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. Sr. VP of Protein Science NA
Dr. Arlette H. Uihlein FCAP, M.D. Sr. VP of Drug Discovery Operations & Medical Director NA
Mr. Raymond F. Vennare CEO & Chairman 1953
Mr. Joshua Blacher M.B.A. Interim Chief Financial Officer 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…